Gentile HelpLine: come organizzare il viaggio durante le vacanze
Dear HelpLine, I am thinking of traveling to see family this year for the holidays, but this would be the first time taking my wife since she was diagnosed with FTD 2 years ago. Is there anything you can share with me about traveling with someone with FTD? For many people, the holiday season is…
Per saperne di piùUna conversazione con il vicepresidente dello sviluppo clinico di Alector
Earlier this year, the biopharmaceutical company Alector announced that the U.S. Food and Drug Administration (FDA) had granted a “breakthrough therapy designation” to latozinemab, the company’s investigational drug designed to address FTD caused by a variant in the GRN gene. The special designation enables expedited regulatory review of therapies intended to treat serious conditions. A…
Per saperne di piùVesper Bio annuncia il completamento con successo dello studio di fase 1 per un trattamento potenzialmente modificante la malattia per FTD-GRN
Biotechnology company Vesper Bio announced in early September that the phase 1 clinical trial for its potentially disease-modifying treatment for FTD-GRN has successfully concluded. The company noted data from the trial demonstrated excellent safety and tolerability of the orally administered drug VES001. In FTD caused by an inherited GRN mutation, the production of the essential…
Per saperne di più24 novembre 2024: incontro di persona a Manchester, NH
Join and learn from others who understand the FTD journey at this in-person AFTD Meet & Greet event, hosted by AFTD Ambassador Shirley Gordon and Kevin Rhodes, co-chair of the AFTD Persons with FTD Advisory Council. The event will take place from 7:30 a.m. – 12:00 p.m. on November 24 at St. Catherine of Siena…
Per saperne di piùIncontro di persona a Manchester, NH
Join and learn from others who understand the FTD journey at this in-person AFTD Meet & Greet event, hosted by AFTD Ambassador Shirley Gordon and Kevin Rhodes, co-chair of the AFTD Persons with FTD Advisory Council. RSVP for this event by emailing sgordon@theaftd.org. To learn more, download this flyer.
Per saperne di piùOhio Hybrid Caregiver Lunch and Learn: Demenza frontotemporale
Bring a lunch and join Judy Bearer, ambassador for the Association for Frontotemporal Degeneration, for this lunch and learn event about frontotemporal degeneration (FTD), the most common cause of dementia in adults under 60 (though it can strike adults at any age). We will review possible causes and symptoms, find local resources, and learn how…
Per saperne di piùWebinar AFTD: Diagnosi dell'afasia progressiva primaria
With primary progressive aphasia (PPA), problems with language and communication typically deteriorate gradually over time. Initial symptoms are sometimes attributed to anxiety or stress until the ongoing symptoms become disruptive enough to prompt further assessment by a specialist. This webinar is intended for clinicians to support early detection and accurate diagnosis of PPA. Learners will…
Per saperne di piùDitelo ai vostri legislatori: riautorizzate i finanziamenti per l'Older Americans Act
You may think that because frontotemporal degeneration strikes many people in the middle of their life, that the Older Americans Act may not apply to you. But the OAA provides funding for services for adult family members and other adults who care for individuals with Alzheimer’s disease and related disorders in their home, regardless of…
Per saperne di piùAvanzare la speranza: AFTD ospita la tavola rotonda sulla ricerca FTD del 2024
The FTD Research Roundtable is an annual program designed to accelerate FTD drug development by convening various scientific stakeholders to identify common challenges and advance solutions for FTD clinical trials. Biopharmaceutical companies currently conducting FTD pre-clinical and clinical trials are invited to join the FTD Research Roundtable, and in 2024, we were thrilled to have…
Per saperne di piùAC Immune e Life Molecular Imaging annunciano la designazione Fast Track della FDA per il tracciante PET Tau
La società biofarmaceutica svizzera AC Immune ha annunciato a fine agosto che il suo partner, la società biofarmaceutica tedesca Life Molecular Imaging (LMI), ha ricevuto una Fast Track Designation dalla Food and Drug Administration (FDA) statunitense per un tracciante PET Tau. La PET, o tomografia a emissione di positroni, è una forma di imaging medico che utilizza un tracciante radioattivo per visualizzare…
Per saperne di più
Italian 
English 
Spanish (Mexico) 
French 
German 
Swedish 
Portuguese 
Dutch 
Danish 
Polish 
Spanish (Spain)